

## Influenza B Yamagata lineage egg-derived<sup>1</sup> candidate vaccine viruses for development and production of vaccines for use in the 2026 southern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)<sup>2</sup>

**26 September 2025 (Last updated 23 October 2025)**

### Candidate vaccine viruses (antigenically like B/Phuket/3073/2013 (egg derived) - Accession number (GISAID): EPI\_ISL\_168822

| Parent virus          | Candidate vaccine virus | Type of virus or reassortant | Developing institute | Available from        |
|-----------------------|-------------------------|------------------------------|----------------------|-----------------------|
| B/Phuket/3073/2013    | Wild type virus         |                              |                      | WHO CCs<br>MHRA, UK*  |
|                       | BVR-1B                  | Classical                    | Seqirus              | VIDRL, Australia      |
| B/California/12/2015  | Wild type virus         |                              |                      | CDC, USA              |
|                       | BX-59A                  | Classical                    | NYMC                 | NYMC, USA             |
|                       | BX-59B                  |                              |                      | NYMC, USA             |
| B/Brisbane/9/2014     | Wild type virus         |                              |                      | WHO CCs<br>MHRA, UK*  |
| B/Utah/09/2014        | Wild type virus         |                              |                      | CDC, USA<br>MHRA, UK* |
| B/Arizona/10/2015     | BX-63                   | Classical                    | NYMC                 | NYMC, USA             |
|                       | BX-63A                  |                              |                      | NYMC, USA             |
| B/Hong Kong/3417/2014 | Wild type virus         |                              |                      | NYMC, USA             |
|                       | BX-57                   | Classical                    | NYMC                 | NYMC, USA             |

\*B/Yamagata viruses may be requested for manufacture of quadrivalent vaccines with written justification required ([standards@mhra.gov.uk](mailto:standards@mhra.gov.uk))

#### Institutes contact details for candidate vaccine virus orders/information:

**CDC:** [InfluenzaVirusSurveillance@cdc.gov](mailto:InfluenzaVirusSurveillance@cdc.gov) (Subject: CVV request)

**MHRA:** [standards@mhra.gov.uk](mailto:standards@mhra.gov.uk) or [enquiries@mhra.gov.uk](mailto:enquiries@mhra.gov.uk)

**NYMC:** [andrew\\_fulvini@nymc.edu](mailto:andrew_fulvini@nymc.edu)

**VIDRL:** [enquiries@influenzacentre.org](mailto:enquiries@influenzacentre.org)

**WHO CCs and ERLs:** [http://www.who.int/influenza/gisrs\\_laboratory/collaborating\\_centres](http://www.who.int/influenza/gisrs_laboratory/collaborating_centres)

<sup>1</sup> For cell-derived candidate vaccine viruses and reference reagents please see <https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>

<sup>2</sup> <https://www.who.int/initiatives/who-listed-authority-reg-authorities>

## Reference antigens (freeze-dried)

| Parent virus       | Starting materials      |             | Ref Ag lot number | Unitage (µg HA/ml) | Available from |
|--------------------|-------------------------|-------------|-------------------|--------------------|----------------|
|                    | Candidate vaccine virus | Egg or cell |                   |                    |                |
| B/Phuket/3073/2013 | Wild type               | Egg         | B(y)-Ag-2112      | 60                 | CBER/FDA, USA  |
|                    |                         |             | 21/136            | 66                 | MHRA, UK       |
|                    |                         |             | 24/182            | 49                 |                |
|                    |                         |             | 2024BYA           | 67                 | NIID, Japan    |
|                    | BVR-1B                  | Egg         | 2023/142B         | 88                 | TGA, Australia |

## Sheep antisera

| Purified HA from        |             | Order Lot number | Available from |
|-------------------------|-------------|------------------|----------------|
| Parent virus            | Egg or Cell |                  |                |
| B/Phuket/3073/2013-like | Egg         | B(y)-Ab-2215     | CBER/FDA, USA  |
|                         |             | 22/132           | MHRA, UK       |
|                         |             | 2021BY-1         | NIID, Japan    |
|                         |             | AS449            | TGA, Australia |
|                         |             | AS449-1          |                |

**WHO Essential Regulatory Laboratories (ERLs) contact details for reagent orders and other information:**

**MHRA:** [standards@mhra.gov.uk](mailto:standards@mhra.gov.uk) or [enquiries@mhra.gov.uk](mailto:enquiries@mhra.gov.uk)

**NIID:** [flu-vaccine@nih.go.jp](mailto:flu-vaccine@nih.go.jp)

**TGA:** [influenza.reagents@tga.gov.au](mailto:influenza.reagents@tga.gov.au)

For reagents available from **CBER**, email [CBERShippingRequests@fda.hhs.gov](mailto:CBERShippingRequests@fda.hhs.gov).

For information of other type and subtype candidate vaccine viruses and potency testing reagents, please go to: (<https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>).

For general enquiries, please contact [gisrs-whohq@who.int](mailto:gisrs-whohq@who.int)